S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
Biden's State of the Union to tout policy wins on economy
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Evacuations urged in Ohio town as train wreck smolders
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
Biden's State of the Union to tout policy wins on economy
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Evacuations urged in Ohio town as train wreck smolders
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
Biden's State of the Union to tout policy wins on economy
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Evacuations urged in Ohio town as train wreck smolders
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
Biden's State of the Union to tout policy wins on economy
A gold storm is coming… (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Evacuations urged in Ohio town as train wreck smolders
A gold storm is coming… (Ad)
EU migration impasse leaves many refugees out in the cold
'Knock at the Cabin' knocks off 'Avatar' at the box office
OTCMKTS:IPSEY

Ipsen - IPSEY Stock Forecast, Price & News

$25.86
-0.56 (-2.12%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$25.86
▼
$26.82
50-Day Range
$25.34
▼
$28.93
52-Week Range
$21.17
▼
$32.51
Volume
700 shs
Average Volume
559 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
0.92%
Price Target
$106.00

Ipsen MarketRank™ Forecast

Analyst Rating
Hold
2.08 Rating Score
Upside/​Downside
309.9% Upside
$106.00 Price Target
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
0.35%
From $2.89 to $2.90 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

See Top Rated MarketRank™ Stocks Here
IPSEY stock logo

About Ipsen (OTCMKTS:IPSEY) Stock

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The Consumer Healthcare segment include brands such as Smecta, a naturally extracted purified clay for the symptomatic treatment of acute diarrhea; Tanakan, a standardized extract from the leaves of Ginkgo biloba for the treatment of various neurological and neuro-sens or ial disorders; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults an

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Stock News Headlines

January 27, 2023 | markets.businessinsider.com
Ipsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOP
January 27, 2023 | msn.com
Ipsen faces another setback for bone disorder drug with EMA panel's rejection
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 27, 2023 | finance.yahoo.com
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
January 20, 2023 | msn.com
Ipsen presents full data showing 'survival benefit' in pancreatic cancer in phase 3 trial
January 20, 2023 | finance.yahoo.com
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
January 20, 2023 | msn.com
Public see pharma workers as Covid heroes, Ipsen survey finds
January 13, 2023 | realmoney.thestreet.com
3 Potential Biotech Buyout Targets
February 5, 2023 | Wall Street Watch Dogs (Ad)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
January 10, 2023 | bizjournals.com
Ipsen to buy liver disease drugmaker for $952M
January 9, 2023 | benzinga.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Albireo (ALBO)
January 9, 2023 | msn.com
Albireo stock jumps 85% as Ipsen set to acquire it for ~$952M
December 27, 2022 | msn.com
Ipsen says FDA rejected treatment for rare bone disorder
December 23, 2022 | au.finance.yahoo.com
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
December 8, 2022 | finance.yahoo.com
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
December 7, 2022 | technews.tmcnet.com
Ellucian's CEO Laura Ipsen Highlighted in Top 50 Women Leaders in SaaS List
November 9, 2022 | seekingalpha.com
Merrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goal
November 9, 2022 | seekingalpha.com
Ipsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patients
October 27, 2022 | finance.yahoo.com
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
October 25, 2022 | markets.businessinsider.com
Ipsen : FDA Postpones Palovarotene Advisory Committee Meeting
September 24, 2022 | msn.com
Ipsen set to invest extra €15m in Dublin
September 6, 2022 | apnews.com
IRLAB’s partner Ipsen Initiates Clinical Studies in Line with Mesdopetam’s Development Plan
August 12, 2022 | finance.yahoo.com
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
August 5, 2022 | finance.yahoo.com
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
August 3, 2022 | finance.yahoo.com
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
August 3, 2022 | markets.businessinsider.com
Ipsen: Phase III RESILIENT Trial Evaluating Onivyde Fails To Meet Primary Endpoint
August 3, 2022 | seekingalpha.com
Ipsen Onivyde fails to improve overall survival of lung cancer patients in phase 3 trial
See More Headlines
Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Company Calendar

Today
2/05/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPSEY
CUSIP
N/A
CIK
N/A
Web
www.ipsen.com
Phone
(315) 833-5000
Fax
33-01-58-33-50-01
Employees
5,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$106.00
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$86.00
Forecasted Upside/Downside
+309.9%
Consensus Rating
Hold
Rating Score (0-4)
2.08
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.88
Quick Ratio
1.75

Sales & Book Value

Annual Sales
$3.55 billion
Price / Sales
N/A
Cash Flow
$3.51 per share
Price / Cash Flow
7.37
Book Value
$9.72 per share
Price / Book
2.66

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.98

Key Executives

  • David G. Loew
    Chief Executive Officer & Director
  • Aymeric Le Chatelier
    Chief Financial Officer & Executive Vice President
  • Aidan Murphy
    Executive Vice President-Technical Operations
  • Howard Mayer
    Executive Vice President-Research & Development
  • Steven Hildemann
    Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors













IPSEY Stock - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 2 sell ratings, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View IPSEY analyst ratings or view top-rated stocks.

What is Ipsen's stock price forecast for 2023?

13 brokers have issued 12-month price objectives for Ipsen's stock. Their IPSEY share price forecasts range from $86.00 to $142.00. On average, they anticipate the company's stock price to reach $106.00 in the next twelve months. This suggests a possible upside of 309.9% from the stock's current price.
View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts.

How have IPSEY shares performed in 2023?

Ipsen's stock was trading at $26.88 at the start of the year. Since then, IPSEY stock has decreased by 3.8% and is now trading at $25.86.
View the best growth stocks for 2023 here.

Are investors shorting Ipsen?

Ipsen saw a increase in short interest in December. As of December 30th, there was short interest totaling 1,000 shares, an increase of 150.0% from the December 15th total of 400 shares. Based on an average daily volume of 2,000 shares, the short-interest ratio is currently 0.5 days.
View Ipsen's Short Interest.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen announced a dividend on Friday, May 27th. Stockholders of record on Wednesday, June 1st will be paid a dividend of $0.2269 per share on Thursday, June 9th. This represents a dividend yield of 0.88%. The ex-dividend date is Tuesday, May 31st.
Read our dividend analysis for IPSEY.

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.92%.
Read our dividend analysis for IPSEY.

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $25.86.

How many employees does Ipsen have?

The company employs 5,700 workers across the globe.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01.

This page (OTCMKTS:IPSEY) was last updated on 2/5/2023 by MarketBeat.com Staff